LY686017: Clinical Trials

5 trials of LY686017, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5

Follow LY686017: new trials by email Literature Review of LY686017 trials Research Report on LY686017

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
VLY-686 (Tradipitant), Placebo - Gastroparesis
Phase 2CompletedVanda Pharmaceuticals1522016-11-012024-08-06
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
VLY-686, Placebo - Treatment-resistant Pruritus Associated With Atopic Dermatitis
Phase 2CompletedVanda Pharmaceuticals692013-12-102024-06-11
A Study in the Treatment of Alcohol Dependence.
LY686017, Placebo - Alcohol Dependence
Phase 2CompletedEli Lilly and Company1902008-12-012019-09-17
Effect of LY686017 on Alcohol Craving
LY686017, Placebo - Alcohol Dependence, Alcoholism
Phase 2CompletedNational Institute on Alcohol Abuse and Alcoholism (NIAAA)662006-03-012010-04-20
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
LY686017, paroxetine, placebo - Social Phobia
Phase 2CompletedEli Lilly and Company1852004-12-012007-02-13

Conditions studied

Alcoholism (2)  ·  Anxiety Disorders (1)  ·  Dermatitis, Atopic (1)  ·  Gastroparesis (1)  ·  Phobia, Social (1)  ·  Pruritus (1)

Sponsors

Eli Lilly and Company (2)  ·  Vanda Pharmaceuticals (2)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1)

Countries

United States (4)  ·  Germany (1)

Results publications

PMID 20018493, PMID 32693185